Chad Messer
Stock Analyst at Lake Street
(0.71)
# 4,139
Out of 5,241 analysts
31
Total ratings
29.03%
Success rate
-14.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chad Messer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGEN Compugen | Initiates: Buy | $6 | $2.81 | +113.52% | 1 | Apr 7, 2026 | |
| IMNM Immunome | Maintains: Buy | $22 → $32 | $19.48 | +64.27% | 2 | Dec 16, 2025 | |
| OSTX OS Therapies | Maintains: Buy | $18 → $17 | $1.69 | +905.92% | 2 | Nov 18, 2025 | |
| GNLX Genelux | Initiates: Buy | $16 | $2.79 | +473.48% | 1 | Oct 21, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $106 | $56.45 | +87.78% | 1 | Sep 23, 2025 | |
| BOLT Bolt Biotherapeutics | Maintains: Buy | $4 → $75 | $4.59 | +1,533.99% | 2 | Aug 15, 2025 | |
| ONCY Oncolytics Biotech | Initiates: Buy | $7 | $0.7741 | +804.28% | 1 | Aug 13, 2025 | |
| COYA Coya Therapeutics | Initiates: Buy | $16 | $4.71 | +239.70% | 1 | Jul 9, 2025 | |
| LTRN Lantern Pharma | Initiates: Buy | $25 | $3.02 | +729.19% | 1 | Apr 2, 2025 | |
| ESPR Esperion Therapeutics | Maintains: Strong Buy | $134 → $114 | $3.14 | +3,536.36% | 3 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $129.05 | -61.26% | 1 | Jul 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $48 | $73.81 | -34.97% | 2 | Jul 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $30 | $48.89 | -38.64% | 3 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $12.77 | +291.54% | 1 | Jun 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $29 | $7.84 | +269.90% | 2 | May 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.24 | +4,066.67% | 1 | Apr 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $86 | $72.77 | +18.18% | 2 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $44 | $15.32 | +187.21% | 2 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $182 → $166 | $16.80 | +888.10% | 1 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $18 | $0.9585 | +1,777.93% | 1 | May 5, 2020 |
Compugen
Apr 7, 2026
Initiates: Buy
Price Target: $6
Current: $2.81
Upside: +113.52%
Immunome
Dec 16, 2025
Maintains: Buy
Price Target: $22 → $32
Current: $19.48
Upside: +64.27%
OS Therapies
Nov 18, 2025
Maintains: Buy
Price Target: $18 → $17
Current: $1.69
Upside: +905.92%
Genelux
Oct 21, 2025
Initiates: Buy
Price Target: $16
Current: $2.79
Upside: +473.48%
Monopar Therapeutics
Sep 23, 2025
Initiates: Buy
Price Target: $106
Current: $56.45
Upside: +87.78%
Bolt Biotherapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $4 → $75
Current: $4.59
Upside: +1,533.99%
Oncolytics Biotech
Aug 13, 2025
Initiates: Buy
Price Target: $7
Current: $0.7741
Upside: +804.28%
Coya Therapeutics
Jul 9, 2025
Initiates: Buy
Price Target: $16
Current: $4.71
Upside: +239.70%
Lantern Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $25
Current: $3.02
Upside: +729.19%
Esperion Therapeutics
Aug 3, 2021
Maintains: Strong Buy
Price Target: $134 → $114
Current: $3.14
Upside: +3,536.36%
Jul 27, 2021
Initiates: Buy
Price Target: $50
Current: $129.05
Upside: -61.26%
Jul 19, 2021
Maintains: Buy
Price Target: $33 → $48
Current: $73.81
Upside: -34.97%
Jun 28, 2021
Maintains: Buy
Price Target: $33 → $30
Current: $48.89
Upside: -38.64%
Jun 17, 2021
Initiates: Buy
Price Target: $50
Current: $12.77
Upside: +291.54%
May 14, 2021
Maintains: Buy
Price Target: $31 → $29
Current: $7.84
Upside: +269.90%
Apr 5, 2021
Initiates: Buy
Price Target: $10
Current: $0.24
Upside: +4,066.67%
Mar 23, 2021
Maintains: Buy
Price Target: $95 → $86
Current: $72.77
Upside: +18.18%
Jan 8, 2021
Maintains: Buy
Price Target: $35 → $44
Current: $15.32
Upside: +187.21%
Jan 8, 2021
Maintains: Buy
Price Target: $182 → $166
Current: $16.80
Upside: +888.10%
May 5, 2020
Maintains: Buy
Price Target: $15 → $18
Current: $0.9585
Upside: +1,777.93%